Bavarian publishes promising cancer data
Bavarian Nordic has published positive data from a phase II trial with the Danish company’s cancer vaccine CV-301. It lends hope to the possibility of expanding the pipeline.
by Martin Havtorn Petersen
New data from a phase II trial with the cancer vaccine CV-301 was published today, and the company behind the vaccine, Denmark-based Bavarian Nordic, calls the results ‘promising’.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
